{"schema_version":"secwatch.filing_event.v1","accession":"0001370053-25-000045","form_type":"8-K","ticker":"ANAB","cik":"0001370053","company_name":"ANAPTYSBIO, INC","filed_at":"2025-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.083201+00:00","generated_at":"2026-05-22T16:52:21.142261+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"AnaptysBio Q1 net loss $39.3M ($1.28/sh); rosnilimab Phase 2b RA data positive; $75M buyback authorized","bullets":["Cash and investments $383M as of March 31, 2025, with cash runway through year-end 2027.","Collaboration revenue $27.8M (up from $7.2M YoY), driven by Jemperli royalties and Vanda license.","R&D expenses $41.2M, up from $37.0M YoY, primarily due to rosnilimab RA/UC and preclinical programs.","Rosnilimab achieved highest-ever CDAI LDA response in 424-patient Phase 2b RA trial; six-month data surpassed competitors.","Initial Phase 2 UC data for rosnilimab expected Q4 2025; GSK Jemperli $1B sales milestone still anticipated 2025/2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001370053-25-000045","json":"https://secwatch.observer/filing/0001370053-25-000045.json","markdown":"https://secwatch.observer/filing/0001370053-25-000045.md","text":"https://secwatch.observer/filing/0001370053-25-000045.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1370053/000137005325000045/0001370053-25-000045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1370053/000137005325000045/anab-20250505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T16:52:21.142261+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}